NO20024195D0 - 4-amino-6,7-dimetoksy-2-(5-metansulfonamido-1,2,3,4- tetrahydroisoquinol-2-yl)-5-(2-pyridinyl)quinazolin-mesylat samtpolymorfer - Google Patents

4-amino-6,7-dimetoksy-2-(5-metansulfonamido-1,2,3,4- tetrahydroisoquinol-2-yl)-5-(2-pyridinyl)quinazolin-mesylat samtpolymorfer

Info

Publication number
NO20024195D0
NO20024195D0 NO20024195A NO20024195A NO20024195D0 NO 20024195 D0 NO20024195 D0 NO 20024195D0 NO 20024195 A NO20024195 A NO 20024195A NO 20024195 A NO20024195 A NO 20024195A NO 20024195 D0 NO20024195 D0 NO 20024195D0
Authority
NO
Norway
Prior art keywords
tetrahydroisoquinol
methanesulfonamido
polymorphs
pyridinyl
dimethoxy
Prior art date
Application number
NO20024195A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024195L (no
Inventor
Patricia Ann Basford
Paul Blaise Hodgson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005200A external-priority patent/GB0005200D0/en
Priority claimed from GB0015900A external-priority patent/GB0015900D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20024195D0 publication Critical patent/NO20024195D0/no
Publication of NO20024195L publication Critical patent/NO20024195L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20024195A 2000-03-03 2002-09-03 4-amino-6,7-dimetoksy-2-(5-metansulfonamido-1,2,3,4- tetrahydroisoquinol-2-yl)-5-(2-pyridinyl)quinazolin-mesylat samtpolymorfer NO20024195L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0005200A GB0005200D0 (en) 2000-03-03 2000-03-03 New salt form
GB0015900A GB0015900D0 (en) 2000-06-28 2000-06-28 New salt form
PCT/IB2001/000244 WO2001064672A1 (en) 2000-03-03 2001-02-23 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs

Publications (2)

Publication Number Publication Date
NO20024195D0 true NO20024195D0 (no) 2002-09-03
NO20024195L NO20024195L (no) 2002-09-03

Family

ID=26243792

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024195A NO20024195L (no) 2000-03-03 2002-09-03 4-amino-6,7-dimetoksy-2-(5-metansulfonamido-1,2,3,4- tetrahydroisoquinol-2-yl)-5-(2-pyridinyl)quinazolin-mesylat samtpolymorfer

Country Status (40)

Country Link
US (1) US6683085B2 (tr)
EP (1) EP1268468B1 (tr)
JP (1) JP3857919B2 (tr)
KR (1) KR100496089B1 (tr)
CN (1) CN1214029C (tr)
AP (1) AP2002002611A0 (tr)
AR (1) AR029482A1 (tr)
AT (1) ATE253570T1 (tr)
AU (1) AU779118B2 (tr)
BG (1) BG106869A (tr)
BR (1) BR0108910A (tr)
CA (1) CA2398963C (tr)
CR (1) CR6731A (tr)
CZ (1) CZ20022858A3 (tr)
DE (1) DE60101157T2 (tr)
DK (1) DK1268468T3 (tr)
EA (1) EA004748B1 (tr)
EE (1) EE200200496A (tr)
ES (1) ES2208565T3 (tr)
GE (1) GEP20043364B (tr)
HK (1) HK1053655A1 (tr)
HN (1) HN2001000036A (tr)
HR (1) HRP20020718A2 (tr)
HU (1) HUP0300006A3 (tr)
IL (1) IL150634A0 (tr)
IS (1) IS6441A (tr)
MA (1) MA26876A1 (tr)
MX (1) MXPA02008665A (tr)
NO (1) NO20024195L (tr)
NZ (1) NZ519672A (tr)
OA (1) OA12186A (tr)
PE (1) PE20011225A1 (tr)
PL (1) PL365070A1 (tr)
PT (1) PT1268468E (tr)
SI (1) SI1268468T1 (tr)
SK (1) SK12282002A3 (tr)
TN (1) TNSN01034A1 (tr)
TR (1) TR200302130T4 (tr)
UA (1) UA72311C2 (tr)
WO (1) WO2001064672A1 (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
DE10223913A1 (de) * 2002-05-29 2003-12-11 Bayer Cropscience Ag Verfahren zur Herstellung spezifischer Kristallmodifikationen polymorpher Substanzen
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CN105596301A (zh) * 2016-01-29 2016-05-25 中国药科大学 一种以异喹啉为基本骨架的p2x7受体拮抗剂的纳米混悬剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914114A (en) 1984-05-28 1990-04-03 Merck Patent Gesellschaft Mit Breschrankter Haftung 3-[4-(4-phenyl-1,2,3,6-tetrahydro-1-pyridyl)butyl]-5-hydroxy-indole methanesulfonate having sedating and anti-parkinsonism properties
EP0281608B1 (de) * 1986-09-16 1990-07-11 MERCK PATENT GmbH Hydroxyindolderivat
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
CZ20022858A3 (cs) 2003-09-17
WO2001064672A1 (en) 2001-09-07
MA26876A1 (fr) 2004-12-20
PE20011225A1 (es) 2001-12-08
EA004748B1 (ru) 2004-08-26
IS6441A (is) 2002-06-25
HK1053655A1 (en) 2003-10-31
HN2001000036A (es) 2001-07-09
HRP20020718A2 (en) 2004-02-29
HUP0300006A3 (en) 2006-01-30
US20020010188A1 (en) 2002-01-24
AP2002002611A0 (en) 2002-09-30
CN1214029C (zh) 2005-08-10
BR0108910A (pt) 2002-12-24
CR6731A (es) 2004-03-11
CN1432010A (zh) 2003-07-23
AU779118B2 (en) 2005-01-06
DE60101157T2 (de) 2004-09-02
UA72311C2 (uk) 2005-02-15
EP1268468A1 (en) 2003-01-02
KR100496089B1 (ko) 2005-06-17
TNSN01034A1 (fr) 2005-11-10
SI1268468T1 (en) 2004-04-30
US6683085B2 (en) 2004-01-27
EP1268468B1 (en) 2003-11-05
ATE253570T1 (de) 2003-11-15
CA2398963C (en) 2006-10-24
PL365070A1 (en) 2004-12-27
ES2208565T3 (es) 2004-06-16
TR200302130T4 (tr) 2004-01-21
AU3588801A (en) 2001-09-12
DE60101157D1 (de) 2003-12-11
PT1268468E (pt) 2004-01-30
SK12282002A3 (sk) 2003-10-07
NZ519672A (en) 2004-06-25
EE200200496A (et) 2004-02-16
MXPA02008665A (es) 2003-02-24
CA2398963A1 (en) 2001-09-07
JP2003525289A (ja) 2003-08-26
GEP20043364B (en) 2004-03-10
JP3857919B2 (ja) 2006-12-13
AR029482A1 (es) 2003-07-02
EA200200826A1 (ru) 2003-02-27
NO20024195L (no) 2002-09-03
BG106869A (bg) 2002-12-29
IL150634A0 (en) 2003-02-12
OA12186A (en) 2006-05-09
HUP0300006A2 (en) 2003-05-28
DK1268468T3 (da) 2004-02-09
KR20020080463A (ko) 2002-10-23

Similar Documents

Publication Publication Date Title
IS6524A (is) 5-alkýlpyrídó(3-3-D)pyrimídín týrósín kínasa tálmar
IS7227A (is) Salt form af E-2-metoxí-N-(3-(4-(3-metýl-pýridín-3-yloxýl)-fenýlamínó)-kínasólín-6-yl)-allýl)-asetamíð, framleiðsla þess og notkun gegn krabbameini
DK1341774T3 (da) Kondenserede heteroaromatiske glucokinase-aktivatorer
EE200300071A (et) Kinasoliini derivaadid
IS6968A (is) Nýir týrósínkínasa tálmar
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
ATE309996T1 (de) Chinolinonderivate als tyrosin-kinase inhibitoren
NO20021820L (no) Tyrosinkinaseinhibitorer
DK1480983T3 (da) Heteroarylsubstituerede 2-pyridinyl- og 2-pyrimidinyl- 6,7,8,9-tetrahydropyrimido[1,2a]pyrimidin-4-onderivater
DE60217669D1 (de) Substitutierte pyrazinone, pyridine und pyrimidine als corticotropin-releasing-factor liganden
ATE303388T1 (de) Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate
ATE253561T1 (de) 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
NO20024195L (no) 4-amino-6,7-dimetoksy-2-(5-metansulfonamido-1,2,3,4- tetrahydroisoquinol-2-yl)-5-(2-pyridinyl)quinazolin-mesylat samtpolymorfer
DK1335906T3 (da) Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
NO20041520L (no) Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin.
IS6758A (is) Kristallaform af 1-[6-klór-5-(tríflúormetýl)-2-pýridinýl]piperasín.hýdróklóríði
HK1061392A1 (en) 5-'4-'2-(N-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione mesylate salt
DK1274700T3 (da) Dihydrobenzopyraner, dihydrobenzothiopyraner og tetrahydroquinoliner til behandling af COX-2-medierede lidelser
FI5113U1 (fi) Syöksytorvi
DK1226136T3 (da) Tyrosinkinaseinhibitor
DK1274687T3 (da) 1,2,3,4-tetrahydroisoquinolinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application